Timo Deutschbein

List of Publications by Year
in descending order

78	4,591	109321 35	106344 65
papers	citations	h-index	g-index

79	79	79	4831
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Adrenal wash-out CT: moderate diagnostic value in distinguishing benign from malignant adrenal masses. European Journal of Endocrinology, 2022, 186, 183-193.	3.7	20
2	Cardiometabolic Disease Burden and Steroid Excretion in Benign Adrenal Tumors. Annals of Internal Medicine, 2022, 175, 325-334.	3.9	53
3	Head/neck paragangliomas: focus on tumor location, mutational status and plasma methoxytyramine. Endocrine-Related Cancer, 2022, 29, 213-224.	3.1	12
4	Improved Diagnostic Accuracy of Clonidine Suppression Testing Using an Age-Related Cutoff for Plasma Normetanephrine. Hypertension, 2022, 79, 1257-1264.	2.7	8
5	Age-dependent and sex-dependent disparity in mortality in patients with adrenal incidentalomas and autonomous cortisol secretion: an international, retrospective, cohort study. Lancet Diabetes and Endocrinology,the, 2022, 10, 499-508.	11.4	55
6	Preanalytical Considerations and Outpatient Versus Inpatient Tests of Plasma Metanephrines to Diagnose Pheochromocytoma. Journal of Clinical Endocrinology and Metabolism, 2022, 107, e3689-e3698.	3.6	4
7	Maternal and fetal outcomes in phaeochromocytoma and pregnancy: a multicentre retrospective cohort study and systematic review of literature. Lancet Diabetes and Endocrinology,the, 2021, 9, 13-21.	11.4	37
8	First German Guideline on Diagnostics and Therapy of Clinically Non-Functioning Pituitary Tumors. Experimental and Clinical Endocrinology and Diabetes, 2021, 129, 250-264.	1.2	12
9	The Interdisciplinary Management of Newly Diagnosed Pituitary Tumors. Deutsches Ärzteblatt International, 2021, 118, 237-243.	0.9	6
10	Method-Specific Cortisol and Dexamethasone Thresholds Increase Clinical Specificity of the Dexamethasone Suppression Test for Cushing Syndrome. Clinical Chemistry, 2021, 67, 998-1007.	3.2	18
11	Mass spectrometry imaging identifies metabolic patterns associated with malignant potential in pheochromocytoma and paraganglioma. European Journal of Endocrinology, 2021, 185, 179-191.	3.7	12
12	Case Report: Consecutive Adrenal Cushingâ€™s Syndrome and Cushingâ€™s Disease in a Patient With Somatic CTNNB1, USP8, and NR3C1 Mutations. Frontiers in Endocrinology, 2021, 12, 731579.	3.5	5
13	Differences between immunotherapy-induced and primary hypophysitisâ€”a multicenter retrospective study. Pituitary, 2021, , 1.	2.9	15
14	Plasma Metabolome Profiling for the Diagnosis of Catecholamine Producing Tumors. Frontiers in Endocrinology, 2021, 12, 722656.	3.5	7
15	Confirmatory testing of primary aldosteronism with saline infusion test and LC-MS/MS. European Journal of Endocrinology, 2021, 184, 167-178.	3.7	11
16	Rationale and design of the cardiovascular status in patients with endogenous cortisol excess study (CV-CORT-EX): a prospective non-interventional follow-up study. BMC Endocrine Disorders, 2021, 21, 11.	2.2	2
17	Plasma metanephrines and prospective prediction of tumor location, size and mutation type in patients with pheochromocytoma and paraganglioma. Clinical Chemistry and Laboratory Medicine, 2021, 59, 353-363.	2.3	32
18	Integrative genomic analysis reveals a conserved role for prolactin signalling in the regulation of adrenal function. Clinical and Translational Medicine, 2021, 11, e630.	4.0	4

#	Article	IF	Citations
19	Response to Letter to the Editor: â€œCT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentalomaâ€• Journal of Clinical Endocrinology and Metabolism, 2020, 105, e3842-e3843.	3.6	0
20	Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes and Endocrinology,the, 2020, 8, 773-781.	11.4	129
21	Sino-European Differences in the Genetic Landscape and Clinical Presentation of Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2020, 105, 3295-3307.	3.6	34
22	Persisting Muscle Dysfunction in Cushingâ€™s Syndrome Despite Biochemical Remission. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4490-e4498.	3.6	29
23	Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. Journal of Hypertension, 2020, 38, 1443-1456.	0.5	190
24	Efficacy of Temozolomide Therapy in Patients With Aggressive Pituitary Adenomas and Carcinomasâ€”A German Survey. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e660-e675.	3.6	34
25	Driver mutations in USP8 wild-type Cushingâ€™s disease. Neuro-Oncology, 2019, 21, 1273-1283.	1.2	65
26	Long-term safety and efficacy of subcutaneous pasireotide in patients with Cushingâ€™s disease: interim results from a long-term real-world evidence study. Pituitary, 2019, 22, 542-551.	2.9	12
27	Computer Vision Technology in the Differential Diagnosis of Cushingâ€™s Syndrome. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 685-690.	1.2	12
28	Impact of USP8 Gene Mutations on Protein Deregulation in Cushing Disease. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2535-2546.	3.6	29
29	Impact of 123I-MIBG Scintigraphy on Clinical Decision-Making in Pheochromocytoma and Paraganglioma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 3812-3820.	3.6	19
30	Long-Term Outcome of Primary Bilateral Macronodular Adrenocortical Hyperplasia After Unilateral Adrenalectomy. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2985-2993.	3.6	49
31	Prognosis of Malignant Pheochromocytoma and Paraganglioma (MAPP-Prono Study): A European Network for the Study of Adrenal Tumors Retrospective Study. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2367-2374.	3.6	103
32	The New Genetic Landscape of Cushingâ€™s Disease: Deubiquitinases in the Spotlight. Cancers, 2019, 11, 1761.	3.7	27
33	Reference intervals for LC-MS/MS measurements of plasma free, urinary free and urinary acid-hydrolyzed deconjugated normetanephrine, metanephrine and methoxytyramine. Clinica Chimica Acta, 2019, 490, 46-54.	1.1	50
34	CT Characteristics of Pheochromocytoma: Relevance for the Evaluation of Adrenal Incidentaloma. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 312-318.	3.6	96
35	Patterns of Lymph Node Recurrence in Adrenocortical Carcinoma: Possible Implications for Primary Surgical Treatment. Annals of Surgical Oncology, 2019, 26, 531-538.	1.5	22
36	Treatment of Refractory Adrenocortical Carcinoma with Thalidomide: Analysis of 27 Patients from the European Network for the Study of Adrenal Tumours Registry. Experimental and Clinical Endocrinology and Diabetes, 2019, 127, 578-584.	1.2	15

#	Article	IF	Citations
37	Adrenomedullary function, obesity and permissive influences of catecholamines on body mass in patients with chromaffin cell tumours. International Journal of Obesity, 2019, 43, 263-275.	3.4	12
38	Plasma steroid metabolome profiling for the diagnosis of adrenocortical carcinoma. European Journal of Endocrinology, 2019, 180, 117-125.	3.7	59
39	Pheochromocytoma and paraganglioma: clinical feature-based disease probability in relation to catecholamine biochemistry and reason for disease suspicion. European Journal of Endocrinology, 2019, 181, 409-420.	3.7	58
40	A high rate of modestly elevated plasma normetanephrine in a population referred for suspected PPGL when measured in a seated position. European Journal of Endocrinology, 2019, 181, 301-309.	3.7	25
41	Metabolic impact of pheochromocytoma/paraganglioma: targeted metabolomics in patients before and after tumor removal. European Journal of Endocrinology, 2019, 181, 647-657.	3.7	19
42	Targeting CXCR4 (CXC Chemokine Receptor Type 4) for Molecular Imaging of Aldosterone-Producing Adenoma. Hypertension, 2018, 71, 317-325.	2.7	77
43	Treatment of aggressive pituitary tumours and carcinomas: results of a European Society of Endocrinology (ESE) survey 2016. European Journal of Endocrinology, 2018, 178, 265-276.	3.7	196
44	Role of MDH2 pathogenic variant in pheochromocytoma and paraganglioma patients. Genetics in Medicine, 2018, 20, 1652-1662.	2.4	45
45	Biochemical Diagnosis of Chromaffin Cell Tumors in Patients at High and Low Risk of Disease: Plasma versus Urinary Free or Deconjugated O-Methylated Catecholamine Metabolites. Clinical Chemistry, 2018, 64, 1646-1656.	3.2	121
46	Surviving ectopic Cushingâ€™s syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushingâ€™s disease during long-term follow-up. European Journal of Endocrinology, 2018, 179, 109-116.	3.7	24
47	Somatic USP8 mutations are frequent events in corticotroph tumor progression causing Nelsonâ€™s tumor. European Journal of Endocrinology, 2018, 178, 57-63.	3.7	37
48	Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. Cancer Cell, 2017, 31, 181-193.	16.8	532
49	Cortisol-related metabolic alterations assessed by mass spectrometry assay in patients with Cushing's syndrome. European Journal of Endocrinology, 2017, 177, 227-237.	3.7	23
50	Persistence of myopathy in Cushingâ€™s syndrome: evaluation of the German Cushingâ€™s Registry. European Journal of Endocrinology, 2017, 176, 737-746.	3.7	57
51	Anthropometric factors have significant influence on the outcome of the GHRHâ€“arginine test: establishment of normative data for an automated immunoassay specifically measuring 22â€‰kDa human growth hormone. European Journal of Endocrinology, 2017, 176, 273-281.	3.7	8
52	Gemcitabine-Based Chemotherapy in Adrenocortical Carcinoma: A Multicenter Study of Efficacy and Predictive Factors. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 4323-4332.	3.6	79
53	PheoSeq. Journal of Molecular Diagnostics, 2017, 19, 575-588.	2.8	63
54	Outcome after resection of Adrenocortical Carcinoma liver metastases: a retrospective study. BMC Cancer, 2017, 17, 522.	2.6	29

#	Article	IF	Citations
55	Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell, 2016, 29, 723-736.	16.8	482
56	Salvage Treatment of Adrenocortical Carcinoma with Trofosfamide. Hormones and Cancer, 2016, 7, 211-218.	4.9	16
57	High evening salivary cortisol is an independent predictor of increased mortality risk in patients with systolic heart failure. International Journal of Cardiology, 2016, 203, 69-73.	1.7	22
58	Lack of Ubiquitin Specific Protease 8 (USP8) Mutations in Canine Corticotroph Pituitary Adenomas. PLoS ONE, 2016, 11, e0169009.	2.5	7
59	Pregnancy in Women Previously Treated for an Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 4604-4611.	3.6	19
60	Major Prognostic Role of Ki67 in Localized Adrenocortical Carcinoma After Complete Resection. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 841-849.	3.6	274
61	Prognostic Value of Aldosterone and Cortisol in Patients Hospitalized for Acutely Decompensated Chronic Heart Failure With and Without Mineralocorticoid Receptor Antagonism. Journal of Cardiac Failure, 2015, 21, 208-216.	1.7	17
62	Expression of <scp>LIN</scp>28 and its regulatory micro<scp>RNA</scp>s in adult adrenocortical cancer. Clinical Endocrinology, 2015, 82, 481-488.	2.4	25
63	Measurements of plasma metanephrines by immunoassay vs liquid chromatography with tandem mass spectrometry for diagnosis of pheochromocytoma. European Journal of Endocrinology, 2015, 172, 251-260.	3.7	47
64	Computed tomography criteria for discrimination of adrenal adenomas and adrenocortical carcinomas: analysis of the German ACC registry. European Journal of Endocrinology, 2015, 172, 415-422.	3.7	43
65	The New Molecular Landscape of Cushing's Disease. Trends in Endocrinology and Metabolism, 2015, 26, 573-583.	7.1	26
66	Treatment of Primary Hypophysitis in Germany. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3460-3469.	3.6	88
67	Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature. Clinical Endocrinology, 2015, 82, 84-90.	2.4	21
68	Diagnosis of Primary Hypophysitis in Germany. Journal of Clinical Endocrinology and Metabolism, 2015, 100, 3841-3849.	3.6	98
69	Mitotane Inhibits Sterol-O-Acyl Transferase 1 Triggering Lipid-Mediated Endoplasmic Reticulum Stress and Apoptosis in Adrenocortical Carcinoma Cells. Endocrinology, 2015, 156, 3895-3908.	2.8	153
70	CYP2W1 Is Highly Expressed in Adrenal Glands and Is Positively Associated with the Response to Mitotane in Adrenocortical Carcinoma. PLoS ONE, 2014, 9, e105855.	2.5	41
71	EJE PRIZE 2014: Current and evolving treatment options in adrenocortical carcinoma: where do we stand and where do we want to go?. European Journal of Endocrinology, 2014, 171, R1-R11.	3.7	37
72	Prognostic Role of Overt Hypercortisolism in Completely Operated Patients with Adrenocortical Cancer. European Urology, 2014, 65, 832-838.	1.9	121

#	Article	IF	Citations
73	The Role of Surgery in the Management of Recurrent Adrenocortical Carcinoma. Journal of Clinical Endocrinology and Metabolism, 2013, 98, 181-191.	3.6	132
74	Low SGK1 Expression in Human Adrenocortical Tumors Is Associated with ACTH-Independent Glucocorticoid Secretion and Poor Prognosis. Journal of Clinical Endocrinology and Metabolism, 2012, 97, E2251-E2260.	3.6	38
75	Salivary cortisol as a diagnostic tool for Cushing's syndrome and adrenal insufficiency: improved screening by an automatic immunoassay. European Journal of Endocrinology, 2012, 166, 613-618.	3.7	71
76	Influence of various confounding variables and storage conditions on metanephrine and normetanephrine levels in plasma. Clinical Endocrinology, 2010, 73, 153-160.	2.4	44
77	Diagnosis of secondary adrenal insufficiency in patients with hypothalamicâ€“pituitary disease: comparison between serum and salivary cortisol during the high-dose short synacthen test. European Journal of Endocrinology, 2009, 160, 9-16.	3.7	51
78	Late-night and low-dose dexamethasone-suppressed cortisol in saliva and serum for the diagnosis of cortisol-secreting adrenal adenomas. European Journal of Endocrinology, 2009, 161, 747-753.	3.7	25